Medtronic Introduces Updated iPro(TM)2 myLog App with FoodPrint(TM) Report Enhancing Diagnostic CGM for People with Diabetes
June 19 2018 - 9:00AM
Expanded
Relationship with Nutrino's FoodPrint Will Leverage Food Data
Analytics Across Diabetes Portfolio
DUBLIN - June 19, 2018 -
Medtronic (NYSE:MDT), the global leader in medical technology,
today announced the availability of the updated iPro(TM)2 myLog app
with FoodPrint(TM) Report. The iPro2 myLog app offers a simple way
for clinics to import patients' logged data during their
professional iPro2 continuous glucose monitoring (CGM) evaluation.
With the addition of the FoodPrint report, patients' meals are
graded based on their body's unique glucose reaction, making it
easy for them to understand the link between meals and glucose
variability.
The iPro2 myLog app, now powered by Nutrino, a
leading AI (artificial intelligence) personalized nutrition
analysis platform, is used during a professional iPro2 CGM
evaluation for the patient to log their blood glucose (BGs), food
and activity. Meal logging is easy; patients simply take a photo of
each meal and snack. Upon completion of the 6-day CGM evaluation,
the information from the app is synchronized with sensor glucose
data and creates two unique reports - the Pattern Snapshot report
and the new FoodPrint report. The Pattern Snapshot report shows
critical glucose information such as time in target glucose range,
identified patterns of glucose variability, and a clear graph of
the full glucose tracing. The FoodPrint report shows pictures of
meals taken for breakfast, lunch and dinner and scores (A, B, C, D
or F) each meal based on the body's glucose reaction. Together
these reports help the physician and the patient work together to
develop a personalized therapy and treatment plan.
"By making it easier to communicate relevant,
personal insights about food's impact on diabetes, Medtronic arms
physicians and diabetes educators with a powerful coaching tool
that will help drive positive behavior change," said Sheri Dodd,
vice president and general manager for Non-Intensive Diabetes
Therapies (NDT). "Our partnership with Nutrino to infuse more
detail about diet's impact on glucose furthers our goal to make
glucose a vital sign in the treatment of diabetes."
Recognizing the important and intertwined impact
that food has on diabetes, Medtronic has expanded its partnership
with Nutrino, a leader in food data analytics with its flagship
FoodPrint technology. Following two years of successful partnering
and results, this expanded relationship will embed food data and
FoodPrint insights across all the Diabetes Group businesses.
"We are proud to partner with Medtronic to deliver
insights through the FoodPrint report, which can help people across
the diabetes spectrum to better understand their responses to
particular foods," said Yael Glassman, CEO of Nutrino Health.
"We're confident that the addition of FoodPrint into the iPro2
professional CGM evaluation will have a positive impact for
individuals living with type 2 diabetes."
About Nutrino
Nutrino is a leading provider of nutrition-related data services,
analytics, and technologies. At its core, Nutrino strives for
improved universal health by enabling AI-led analysis of how
nutritional intake will affect a person's health. Nutrino has also
built a leading food database and nutrition data insights platform,
collating data from millions of access points and food items
globally. Nutrino helps people discover their FoodPrint, a
personalized assessment of their personal response to different
foods. Smarter about food and smarter about people, Nutrino's
revolutionary approach uncovers connections of the way individuals
and groups metabolize and respond to foods. Nutrino is building a
global FoodPrint. To find out more, click here.
About Diabetes Group at
Medtronic
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 86,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
All other brands, product names, company names,
trademarks and service marks are the properties of their respective
owners. All rights reserved.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Pamela Reese
Medtronic
Public Relations
+1-818-576-3398
Ryan Weispfenning
Medtronic
Investor Relations
+1-763-505-4626
Jill Burkes
Nutrino
Public Relations
+1-917-722-5054
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024